Optimizing long-term prevention of cardiovascular disease after acute coronary syndrome
Official title: Guided Optimisation of Long-term Disease rEduction in secoNdary Prevention of CVD (GOLDEN). A Prospective Observational Study of Long-term Outcomes.
Run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · NCT06637657 · Data updated 2026-11-12
This study tests if starting a complete medication plan right away for people hospitalized with heart disease can help prevent serious heart problems better than the usual gradual approach.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 5586 (estimated) |
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Academic / other |
| Locations | 1 site (Amsterdam) |
| Status | Recruiting |
| Started | July 9, 2024 |
| Main results expected | January 2029 |
| Study ends | January 2029 |
| Registry record updated | October 15, 2024 |
| Trial ID | NCT06637657 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 18 years who have experienced an acute coronary syndrome event or coronary revascularization.
✕Probably not a fit
Patients who are pregnant, breastfeeding, or on dialysis may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study evaluates the effectiveness of a 'first-time-right' pharmacological treatment strategy for patients hospitalized with coronary artery disease. It compares this approach, which involves immediate initiation of a comprehensive medication plan, to the current practice of incremental titration of medications. The study aims to determine if the new strategy leads to a reduction in major adverse cardiovascular events over a 36-month period. Participants will be monitored through routine clinical visits and online questionnaires to assess outcomes.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the risk of recurrent cardiovascular events in patients with coronary artery disease.
How similar studies have gone: While similar approaches have been discussed in guidelines, this specific 'first-time-right' strategy has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * \>18 years of age (no upper limit) * Coronary event, i.e. ACS or coronary revascularisation * Able to provide informed consent Exclusion Criteria: * (short-term planned) pregnancy or breast feeding * Dialysis
Where it's running
-
Amsterdam UMC
Amsterdam, Netherlands Recruiting
Study contacts
- Principal investigator: Harald T. Jorstad, dr. — Amsterdam UMC
- Study coordinator: Manon van den Bogaart, drs.
- Email: m.vandenbogaart@amsterdamumc.nl
- Phone: 003120 5660703
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Common femoral vein-to-artery diameter ratio to detect elevated LVEDP
Researchers test whether the ratio of the common femoral vein to artery diameters, measured by ultrasound, can flag elevated LV end-diastolic pressure in patients having coronary angiography.
-
Intrahospital flu vaccine for adults with high cardiovascular risk when admitted for ACS or heart failure
This study tests whether offering a flu vaccine at the bedside during a hospital stay, along with counseling, increases vaccination rates for adults with acute coronary syndrome or heart failure who are at high cardiovascular risk.
-
Digital lifestyle platform after rehabilitation to support self-management
A digital, patient-facing platform is being tested to see if people who recently finished inpatient rehabilitation will use it and benefit from personalized lifestyle guidance at home.
-
AI-driven Medipixel fractional flow reserve to guide PCI
This test checks whether an AI-based, angiography-derived Medipixel FFR method can guide PCI as safely and effectively as standard invasive pressure-wire FFR in adults with coronary artery disease.
-
Freesolve resorbable magnesium scaffold vs. Xience stent for up to two new heart artery lesions
This trial tests whether the Freesolve resorbable magnesium scaffold works as well as the Xience drug-eluting stent for treating up to two new coronary artery lesions in adults.
-
AI-assisted interpretation of chest pain CT in the emergency department
A pragmatic randomized trial tests whether an AI tool (Angiomics) helps emergency physicians interpret coronary CT angiography in adults with acute chest pain.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.